Менопаузальный остеопороз и витамин D

1. Kanis J.A.; on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical 
Report. WHO Collaborating Centre, University of Sheffield, UK; 2008.

2. Российская ассоциация эндокринологов. Остеопороз. Клинические рекомендации МЗ РФ. М.; 2016. 104с.

3. Kanis J.A., McCloskey E.V., Johansson H., Cooper C., Rizzoli R., Reginster J.Y. European guidance for the diagnosis and management of osteoporosis in postmenopausalwomen. Osteoporos. Int. 2013; 24(1): 23-57.

4. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я. Остеопороз – от редкого симптома эндокринных болезней до безмолвной эпидемии 20-21 века. Проблемы эндокринологии. 2011; 57(1): 35-45.

5. Melton L.J., Kearns A.E., Atkinson E.J., Bolander M.E., Achenbach S.J., Huddleston J.M. et al. Secular trends in hip fracture incidence and recurrence. Osteoporos. Int. 2009; 20(5): 687-94.

6. Cromer B.A. Menstrual cycle and bone health in adolescent. Ann. N.Y. Acad. Sci. 2008; 1135: 196-203.

7. Norman A.W. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am. J. Clin. Nutr. 2008; 88(2): 491S-9S.

8. Christakos S., Dhawan P., Verstuyf A., Verlinden L., Carmeliet G. Vitamin D: Metabolism, molecular mechanism of action, and pleiotropic effects. Physiol. Rev. 2016; 96(1): 365-408.

9. Tiosano D., Hadad S., Chen Z., Nemirovsky A., Gepstein V., Militianu D. et al. Calcium absorption, kinetics, bone density, and bone structure in patients with hereditary vitamin D-resistant rickets. J. Clin. Endocrinol. Metab. 2011; 96(12): 3701-9.

10. Xue Y., Fleet J.C. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology. 2009;136(4): 1317-27.

11. Lieben L., Masuyama R., Torrekens S., Van Looveren R., Schrooten J., Baatsen P. et al. Normocalcemia is maintained in mice under conditions of calcium malabsorption by vitamin D-induced inhibition of bone mineralization. J. Clin. Invest. 2012; 122(5): 1803-15.

12. Meyer M.B., Benkusky N.A., Lee C.H., Pike J.W. Genomic determinants of gene regulation by 1,25-dihydroxyvitamin D3 during osteoblast-lineage cell differentiation. J. Biol. Chem. 2014; 289(28): 19539-54.

13. Yamamoto Y., Yoshizawa T., Fukuda T., Shirode-Fukuda Y., Yu T., Sekine K. et al. Vitamin D receptor in osteoblasts is a negative regulator of bone mass control. Endocrinology. 2013; 154(3): 1008-20.

14. Wang Y., Zhu J., DeLuca H.F. Identification of the vitamin D receptor in osteoblasts and chondrocytes but not osteoclasts in mouse bone. J. Bone Miner. Res. 2014; 29(3): 685-92.

15. Nakashima T., Hayashi M., Fukunaga T., Kurata K., Oh-Hora M., Feng J.Q. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 2011; 17(10): 1231-4.

16. Viguet-Carrin S., Follet H., Gineyts E., Roux J.P., Munoz F., Chapurlat R. et al. Association between collagen cross-links and trabecular microarchitecture properties of human vertebral bone. Bone. 2010;46(2): 342-7.

17. Saito M., Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos. Int. 2010; 21(2): 195-214.

18. Yamauchi M., Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012; 52: 113-33.

19. Nagaoka H., Mochida Y., Atsawasuwan P., Kaku M., Kondoh T., Yamauchi M. 1,25(OH)2D3 regulates collagen quality in an osteoblastic cell culture system. Biochem. Biophys. Res. Commun. 2008; 377(2): 674-8.

20. Priemel M., von Domarus C., Klatte T.O., Kessler S., Schlie J., Meier S. et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 2010; 25(2): 305-12.

21. Kanis J.A., McCloskey E., Johansson H., Oden A., Leslie W.D. FRAX® with and without bone mineral density. Calcif. Tissue Int. 2012; 90: 1-13.

22. Ott S. Osteoporosis and bone physiology. World Health Organizations definitions. http://www.uwcme.org/courses/bonephys/whodef.html

23. Civitelli R., Armamento-Villareal R., Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos. Int. 2009; 20(6): 843-51.

24. Kanis J.A., Johansson H., Oden A., McCloskey E.V. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009; 44(6): 1049-54.

25. Kanis J.A., Johansson H., Oden A., McCloskey E.V. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010; 47(4): 729-35.

26. de Villiers T.J., Chines A.A., Palacios S., Lips P., Sawicki A.Z., Levine A.B. et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos. Int. 2011; 22(2): 567-76.

27. Harris S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr. Med. Res. Opin. 2008; 24(1): 237-45.

28. Rizzoli R., Reginster J.Y., Boonen S., Breart G. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 2011; 89(2): 91-104.

29. Pazianas M., Compston J., Huang C.L. Atrial fibrillation and bisphosphonate therapy. J. Bone Miner. Res. 2010; 25: 2-10.

30. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304(6): 657-63.

31. Hartle J.E., Tang X., Kirchner H.L., Bucaloiu I.D., Sartorius J.A., Pogrebnaya Z.V. et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am. J. Kidney Dis. 2012; 59(5): 636-44.

32. Lecart M.P., Reginster J.Y. Current options for the management of postmenopausal osteoporosis. Expert Opin. Pharmacother. 2011; 12(16): 2533-52.

33. Cummings S.R., San Martin J., McClung M.R., Siris E.S., Eastell R., Reid I.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 2009; 361(8): 756-65.

34. Middleton E.T., Steel S.A., Aye M., Doherty S.M. The effect 
of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J. Bone Miner. Res. 2010; 25(3): 455-62.

35. Kanis J.A., Johansson H., Oden A., McCloskey E.V. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos. Int. 2011; 22(8): 2347-55.

36. Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009; 14(10): 3869-80.

37. Saito M., Shiraishi A., Ito M., Sakai S., Hayakawa N., Mihara M., Marumo K. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone. 2010; 46(4): 1170-9.

38. Nagaoka H., Terajima M., Yamada S., Azuma Y., Chida T., Yamauchi M. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J. Orthopaed. Res. 2014; 32(8): 1030-6.

39. Jiang Y., Zhang Z.L., Zhang Z.L., Zhu H.M., Wu Y.Y., Cheng Q. et al. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clin. Interv. Aging. 2014; 9: 121-7.

40. O’Donnell S., Moher D., Thomas K., Hanley D.A., Cranney A. Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J. Bone Miner. Metab. 2008; 26(6): 531-42.

41. Desmarchelier C., Margier M., Prévéraud D.P., Nowicki M., Rosilio V., Borel P., Reboul E. Comparison of the micellar incorporation and the intestinal cell uptake of cholecalciferol, 25-hydroxycholecalciferol and 1-α-hydroxycholecalciferol. Nutrients. 2017; 9(10). pii: E1152.

42. Ершова О.Б., Белова К.Ю., Назарова А.В. Активные метаболиты витамина D: применение при остеопорозе. Остеопороз и остеопатии. 2009; 1: 27-32.

43. Suzuki T., Nakamura Y., Tanaka M., Kamimura M., Ikegami S., Uchiyama S., Kato H. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Mod. Rheumatol. 2018;28(2): 376-9.

44. Osteoporosis and Bone Mineral Society of the Chinese Medical Association. Primary osteoporosis diagnosis and treatment guidelines. Chin. J. Osteoporos. Bone Miner. Res. 2011; 4(1): 2-17.

45. Shiraishi A., Miyabe S., Nakano T., Umakoshi Y., Ito M., Mihara M. The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet. Disord. 2009; 10: 66.

46. Koundourakis N.E., Avgoustinaki P.D., Malliaraki N., Margioris A.N. Muscular effects of vitamin D in young athletes and non-athletes and in the elderly. Hormones. 2016; 15(4): 471-88.

47. Murad M.H., Elamin K.B., Abu Elnour N.O., Elamin M.B., Alkatib A.A., Fatourechi M.M. et al. Clinical review: the effect of vitamin D on falls: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2011; 96(10): 2997-3006.

48. Cameron I.D., Gillespie L.D., Robertson M.C., Murray G.R., Hill K.D., Cumming R.G., Kerse N. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database Syst. Rev. 2012; (12): CD005465.

49. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R. et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339: b3692.

Поступила 08.06.2018

Принята в печать 22.06.2018